SCHEDULE: Vanguard Group Reports 0% Novavax Beneficial Ownership

The Vanguard Group has reported a 0% beneficial ownership in Novavax Inc. common stock following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 7 to Schedule 13G for Novavax Inc. common stock.
• The filing indicates that The Vanguard Group now holds 0 shares, representing 0% of the class of securities.
• This change is due to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a procedural update regarding an institutional investor's reporting structure and does not reflect a positive or negative assessment of Novavax Inc.'s business or prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Novavax Inc.'s future performance or operations.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that this filing represents a routine disclosure for large institutional investors like The Vanguard Group, reflecting an adjustment in their internal reporting structure rather than a change in investment strategy or a divestment decision related to Novavax Inc.'s fundamentals. Such realignments are common for diversified asset managers to comply with regulatory guidelines for beneficial ownership reporting.

Stakeholder Impact

• Shareholders of Novavax Inc. may observe a change in reported institutional ownership, but this specific filing indicates a reporting realignment by Vanguard rather than a direct investment decision impacting Novavax's stock.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership of Novavax Inc. securities separately on a disaggregated basis.

Key Dates

Keywords

Novavax, Vanguard Group, Schedule 13G, beneficial ownership, institutional ownership, common stock, internal realignment